Giant Scrotal Fibrolipoma.
Thessaloníki, Greece. In Rare Tumors, Jan 2016
On immunohistochemistry, MDM2 and CDK4 were not expressed.
Peptide-based inhibitors of protein-protein interactions.
Wrocław, Poland. In Bioorg Med Chem Lett, Jan 2016
Importantly, numerous specific protein-protein interactions (e.g., p53-HDM2 and Bcl-2-BH3 domains) were found to be involved in the development of several diseases, including various types of cancer.
DNA replication stress as a hallmark of cancer.
Genève, Switzerland. In Annu Rev Pathol, 2014
The sustained proliferation hallmark can be explained by mutations in oncogenes and tumor suppressors that regulate cell growth, whereas the escape from apoptosis hallmark can be explained by mutations in the TP53, ATM, or MDM2 genes.
L-6/STAT3/ARF: the guardians of senescence, cancer progression and metastasis in prostate cancer.
Vienna, Austria. In Swiss Med Wkly, 2014
The identification of the alternative reading frame protein (ARF) / murine double minute protein (MDM2) / p53 tumour suppressor pathway potentially involving the IL-6/STAT3 axis as a restricting factor in prostate cancer deficient in the tumour suppressor phosphatase and tensin homologue (PTEN) opened new avenues to currently available therapies.
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).
More papers using
Villejuif, France. In Lancet Oncol, 2014
117 (39%) of 297 patients with genomic tests available presented with rare genomic alterations (defined as occurring in less than 5% of the general population), including AKT1 mutations, and EGFR, MDM2, FGFR2, AKT2, IGF1R, and MET high-level amplifications.